Alpha-Synuclein Aggregation Pathway

Overview

Alpha-synuclein aggregation represents one of the central pathological hallmarks of Parkinson’s disease (PD) and related synucleinopathies. The pathological accumulation of misfolded alpha-synuclein protein into Lewy bodies and Lewy neurites characterizes the majority of PD cases and provides a mechanistic link between genetic risk factors and sporadic disease^{1Alpha-synuclein in Lewy bodies1997 · Nature · DOI 10.1038/42166Open reference}. Understanding the pathways governing alpha-synuclein homeostasis, misfolding, aggregation, and propagation is essential for developing disease-modifying therapies targeting the proteinopathic basis of these neurodegenerative disorders.

The alpha-synuclein protein is encoded by the SNCA gene and is abundant in the brain, particularly in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists as a natively unfolded monomer that can adopt alpha-helical conformations upon membrane binding. However, various genetic, environmental, and age-related factors can trigger the protein’s misfolding into beta-sheet rich oligomers and fibrils that serve as the building blocks of Lewy pathology^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}.

The progression of alpha-synuclein pathology follows a predictable pattern in PD, beginning in the lower brainstem and olfactory bulb, advancing to the midbrain (including the substantia nigra), and eventually affecting cortical regions^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}. This staging system has been validated in multiple cohorts and provides a framework for understanding disease progression.

Molecular Biology of Alpha-Synuclein

Protein Structure and Function

Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene located on chromosome 4q21. The protein comprises three distinct domains^{4The NAC domain is essential for alpha-synuclein aggregation1996 · J Biol Chem · DOI 10.1074/jbc.271.32.19789Open reference}:

1. N-terminal region (1-60): Contains seven imperfect repeats of the sequence KTKEGV that mediate lipid binding and form alpha-helical structures upon association with membranes. This region also contains the sites of familial PD mutations (A30P, A53T, E46K, G51D, H50Q).

2. Central hydrophobic region (61-95): Known as the non-amyloid-beta component (NAC) domain, this region is highly prone to aggregation and is essential for fibril formation. The NAC domain contains residues critical for beta-sheet formation.

3. C-terminal region (96-140): Acidic and proline-rich, this domain is intrinsically disordered and may serve as a chaperone-like regulatory domain. The C-terminal tail also contains sites for phosphorylation (Ser129) and other post-translational modifications.

Under normal conditions, alpha-synuclein participates in synaptic vesicle pool management, dopamine transmission regulation, and neuronal plasticity. The protein shuttles between cytosolic and membrane-associated pools, with its membrane binding being regulated by post-translational modifications and cellular signaling events^{5Propagation of alpha-synuclein pathology2019 · Neuron · DOI 10.1016/j.neuron.2019.04.031Open reference}.

Physiological Functions

Beyond its pathological aggregation, alpha-synuclein has important physiological roles:

• Regulation of synaptic vesicle trafficking and clustering

• Modulation of dopamine synthesis and release

• Presynaptic plasticity and long-term potentiation

• Calcium homeostasis

• Lipid metabolism

Transgenic mice lacking alpha-synuclein show relatively mild phenotypes, suggesting functional redundancy, while overexpression leads to neurodegeneration, highlighting the importance of proper regulation.

Post-Translational Modifications

Alpha-synuclein undergoes numerous post-translational modifications that influence its aggregation propensity^{6Alpha-synuclein and tau pathology2020 · Acta Neuropathol · DOI 10.1007/s00401-020-02168-0Open reference}:

• Phosphorylation: Phosphorylation at Ser129 is the predominant modification in Lewy bodies, with approximately 90% of pathological alpha-synuclein being phosphorylated at this site. Kinases including G-protein-coupled receptor kinases (GRKs) and casein kinases contribute to this modification. Ser129 phosphorylation promotes fibril formation and may be a therapeutic target.

• Ubiquitination: Polyubiquitination targets alpha-synuclein for proteasomal degradation, though Lewy body alpha-synuclein is often conjugated to ubiquitin chains that may be atypical (e.g., Lys63-linked). Ubiquitination may be a marker of cellular stress rather than a degradation signal.

• Truncation: C-terminal truncations enhance aggregation propensity and are found in pathological inclusions. Truncated alpha-synuclein (e.g., 1-120) serves as an efficient seed for aggregation of full-length protein.

• Oxidation and nitration: Reactive oxygen and nitrogen species can modify tyrosine residues (Y125, Y133, Y136), promoting aggregation. Oxidized alpha-synuclein shows enhanced oligomerization and neurotoxicity.

• SUMOylation: SUMOylation at Lys102 and Lys96 modulates aggregation, with SUMOylated alpha-synuclein showing reduced fibrillization.

Mechanisms of Aggregation

Nucleation and Oligomerization

The aggregation of alpha-synuclein follows a nucleation-dependent polymerization model^{7Alpha-synuclein in immune cells2022 · Nat Rev Neurol · DOI 10.1038/s41582-022-00639-4Open reference}:

1. Lag phase: Monomeric alpha-synuclein undergoes conformational changes to form transient oligomeric nuclei. This phase can be accelerated by pre-existing seeds (“seeded” aggregation).

2. Growth phase: Addition of monomers to existing nuclei leads to rapid fibril elongation. The fibrils grow through a “dock-lock” mechanism involving conformational conversion of monomers.

3. Plateau phase: Equilibrium between monomers, oligomers, and fibrils is reached.

The toxic oligomeric species formed during aggregation are increasingly recognized as the primary neurotoxic entities, rather than the mature fibrils themselves^{8The role of oligomers in alpha-synuclein diseases2019 · Mol Neurodegener · DOI 10.1186/s13024-019-0341-5Open reference}. These oligomers can be:

• Membrane-permeabilizing: Forming pores that disrupt cellular ion homeostasis

• Synaptic disruptors: Impairing neurotransmitter release and reuptake

• Mitochondrially toxic: Targeting and damaging mitochondrial function

• Prion-like: Capable of seeding further aggregation in a templated manner^{9alpha-Synuclein prion-like properties2018 · Nat Rev Neurol · DOI 10.1038/s41582-018-0014-9Open reference}

Oligomer Types and Toxicity

Alpha-synuclein oligomers exist in multiple forms:

• Protofibrils: Early oligomeric intermediates that can be circular or chain-like

• Annular oligomers: Pore-like structures that disrupt membranes

• Spherical oligomers: Diffuse aggregates with varying toxicity

• Fibrillar intermediates: On-pathway species that mature into fibrils

The specific oligomer species that are most toxic remains an active area of investigation, but evidence suggests that transient, intermediate oligomers may be particularly pathogenic.

Cellular Quality Control Systems

Multiple cellular pathways attempt to prevent alpha-synuclein aggregation:

Prion-Like Propagation

Cell-to-Cell Transmission

A landmark discovery in neurodegeneration research was the recognition that alpha-synuclein pathology can propagate between neurons in a prion-like manner^{9alpha-Synuclein prion-like properties2018 · Nat Rev Neurol · DOI 10.1038/s41582-018-0014-9Open reference}. This process involves:

1. Release: Alpha-synuclein is released from neurons via exocytosis, exosome secretion, and possibly direct membrane transfer. Release is enhanced by neuronal activity and cellular stress.

2. Uptake: Recipient cells internalize extracellular alpha-synuclein via various endocytic pathways, including receptor-mediated endocytosis, direct membrane translocation, and phagocytosis.

3. Seeding: Exogenous alpha-synuclein serves as a template for seeded aggregation of endogenous protein. The conformation of the seed dictates the structure of the resulting aggregates (“strain” concept).

4. Spread: The process repeats, propagating pathology throughout connected brain regions.

This prion-like propagation provides a mechanistic explanation for the staging of Lewy pathology in the brains of PD patients, which follows a predictable pattern beginning in the lower brainstem and advancing to the midbrain and eventually cortical regions^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}0.

Evidence for Prion-Like Spread

Multiple lines of evidence support prion-like propagation:

• Lewy bodies can be detected in grafted neurons years after transplantation into PD brains

• Animal models show that injected alpha-synuclein seeds endogenous pathology

• In vitro experiments demonstrate templated conversion of monomeric alpha-synuclein

• Brain-bank studies show progression patterns consistent with spread

Strains and Polymorphisms

Emerging evidence suggests that alpha-synuclein aggregates can adopt distinct conformational “strains” with different biological properties, potentially explaining the clinical heterogeneity of synucleinopathies. These strains may differ in:

• Fibril morphology (as seen by cryo-EM)

• Seeding potency

• Cellular tropism

• Pathogenicity

Strains may also influence the clinical phenotype, with certain conformations associated with PD vs. DLB vs. MSA.

Genetic Factors

SNCA Mutations and Multiplications

Point mutations in SNCA (A53T, A30P, E46K, H50Q, G51D) and genomic multiplications cause familial PD, demonstrating that dysregulated alpha-synuclein expression is sufficient to cause neurodegeneration^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}1^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}2:

• A53T: Found in the Italian Contursi kindred and several other families, promotes rapid aggregation in cellular and animal models. Leads to early-onset PD (median age 46 years).

• A30P: Identified in a German family, reduces membrane binding while promoting aggregation. Associated with variable onset and progression.

• E46K: Found in Spanish families, enhances aggregation and affects sleep behavior. Recapitulates Lewy body pathology in mice.

• G51D: Rare mutation found in a Japanese family, has complex effects on aggregation and cellular trafficking.

• H50Q: Recently identified mutation with intermediate effects on aggregation.

• SNCA duplication/triplication: First identified in the Iowa kindred, causes LOADs (late-onset autosomal dominant) form of PD^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}3. Gene dosage correlates with age of onset, supporting a toxic gain-of-function mechanism.

Risk Variants

Genome-wide association studies (GWAS) have identified common variants at the SNCA locus as significant risk factors for sporadic PD, highlighting the importance of alpha-synuclein biology even in non-familial disease^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}4. These variants likely influence SNCA expression through regulatory elements in the promoter and intronic regions.

Interactions with Other Proteins

Alpha-Synuclein and Tau

Alpha-synuclein pathology frequently coexists with tau pathology in PD and PD with dementia^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}5^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}6:

• Synergistic toxic effects: Co-aggregation and cross-seeding

• Common upstream mechanisms (e.g., oxidative stress, mitochondrial dysfunction)

• Shared therapeutic targets

Alpha-Synuclein and Amyloid-Beta

In the presence of amyloid pathology (as in AD), alpha-synuclein aggregation is accelerated:

• Amyloid-beta may act as a seed for alpha-synuclein

• Shared mechanisms of cellular vulnerability

• Implications for PD-AD overlap

Therapeutic Implications

Disease-Modifying Strategies

Targeting alpha-synuclein aggregation represents a promising therapeutic approach^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}7:

1. Immunotherapies: Active and passive immunization approaches targeting alpha-synuclein are in clinical development. Examples include:

   • PRX002 (prasinezumab): Anti-alpha-synuclein monoclonal antibody

   • BIIB054 (cinmeron): Antibody targeting oligomeric alpha-synuclein

   • ACI-35: Liposome-based vaccine targeting phosphorylated Ser129

2. Small Molecule Inhibitors: Compounds that prevent aggregation or promote clearance include:

   • Anle138b: Oligomer modulator in clinical trials

   • NPT200-1: Aggregation inhibitor

   • SynuClean-D: Dual inhibitor of alpha-synuclein aggregation

3. Gene Therapy: Viral vector-mediated delivery of genes encoding anti-aggregation proteins or RNA interference targeting SNCA mRNA.

4. Enhancing Clearance: Strategies to boost autophagy and proteasomal degradation of alpha-synuclein, including:

   • mTOR inhibitors (rapamycin)

   • Autophagy inducers (carbamazepine, trehalose)

   • Gene therapy for chaperone proteins

Targeting Propagation

Emerging strategies target the prion-like spread of alpha-synuclein:

• Inhibitors of exosome release

• Blocking cell-to-cell transmission

• Anti-seed antibodies

Biomarkers

Alpha-Synuclein as Biomarker

Alpha-synuclein in biofluids serves as a PD biomarker:

• CSF alpha-synuclein: Reduced total alpha-synuclein in PD; elevated phosphorylated Ser129

• Blood/plasma alpha-synuclein: Technical challenges but promising

• Skin biopsy: Detection of phosphorylated alpha-synuclein

Seed Amplification Assays

Real-time quaking-induced conversion (RT-QuIC) and PMCA can detect pathological alpha-synuclein with high sensitivity and specificity:

• Detects oligomeric/fibrillar species

• Differentiates PD from controls

• May detect pre-clinical disease

Summary

The alpha-synuclein aggregation pathway represents a central mechanism in Parkinson’s disease pathogenesis. The conversion of natively unfolded alpha-synuclein into toxic oligomers and fibrils disrupts multiple cellular processes, including synaptic function, mitochondrial integrity, and proteostasis. The prion-like propagation of pathology provides a framework for understanding disease progression, while the identification of genetic mutations causing familial PD establishes alpha-synuclein dysregulation as a sufficient cause of neurodegeneration. Therapeutic strategies targeting various stages of the aggregation pathway are under active clinical development, offering hope for disease-modifying treatments in Parkinson’s disease.

Oligomer Biology and Toxicity

Structural Characterization of Oligomers

Alpha-synuclein oligomers represent a heterogeneous population of prefibrillar species that form during the aggregation process. These oligomers are increasingly recognized as the primary neurotoxic species in Parkinson’s disease, rather than the mature fibrils that comprise Lewy bodies. ^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}8

The structural properties of toxic oligomers include:

1. Beta-sheet rich conformation: Despite their prefibrillar nature, many oligomers contain beta-sheet secondary structures that distinguish them from natively unfolded monomers

2. Membrane binding capacity: Oligomers exhibit enhanced binding to neuronal membranes, particularly at synaptic terminals

3. Dynamic nature: Oligomeric species are transient and can revert to monomers, disaggregate into fibrils, or continue to grow

4. Surface exposure of hydrophobic regions: The NAC domain becomes more exposed in oligomeric states, enabling membrane interaction and cellular toxicity

Mechanisms of Oligomer-Mediated Neurotoxicity

The toxic effects of alpha-synuclein oligomers on neurons involve multiple interconnected pathways:

Synaptic dysfunction: Oligomeric alpha-synuclein localizes to presynaptic terminals where it disrupts synaptic vesicle trafficking and recycling. Studies in transgenic mice demonstrate that oligomer accumulation correlates with progressive loss of synaptic proteins and impaired neurotransmitter release. ^{2" The synucleinopathies: Twenty years on"2017 · Brain · DOI 10.1093/brain/awx056Open reference}9

Calcium dysregulation: Oligomers can form calcium-permeable pores in neuronal membranes, leading to dysregulated calcium homeostasis. This calcium influx activates downstream pathways including calpain-mediated proteolysis and mitochondrial permeability transition.

Mitochondrial dysfunction: Alpha-synuclein oligomers directly bind to mitochondrial membranes and impair complex I activity. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}0 This creates a vicious cycle where mitochondrial dysfunction increases oxidative stress, which in turn promotes further alpha-synuclein aggregation.

Endoplasmic reticulum stress: Oligomer accumulation in the endoplasmic reticulum triggers the unfolded protein response (UPR) and promotes apoptotic signaling through CHOP and caspase activation.

Targeting Oligomers Therapeutically

Given the central role of oligomers in pathogenesis, several therapeutic strategies specifically target these species:

• Oligomer-specific antibodies: Antibodies that selectively recognize oligomeric conformations over monomers or fibrils

• Small molecule modulators: Compounds like anle138b that shift the aggregation pathway away from toxic oligomers toward inert species

• Seeding inhibitors: Molecules that prevent oligomeric seeds from propagating

Fibril Structure and Lewy Body Formation

Atomic Structure of Alpha-Synuclein Fibrils

Cryo-electron microscopy studies have revealed the atomic structure of alpha-synuclein fibrils, demonstrating that they adopt a cross-beta sheet architecture. The fibril core comprises residues 31-100, forming a double phi-loop structure that stabilizes the fibril. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}1

Key structural features include:

• Steric zipper: The interface between beta-sheets creates a “steric zipper” motif characteristic of amyloid fibrils

• Residue-specific folding: The NAC region (residues 61-95) forms the fibril core

• Polymorphic strains: Different preparation conditions and cellular environments produce structurally distinct fibril morphologies

Lewy Body Composition and Maturation

Lewy bodies are complex intracellular inclusions comprising fibrillar alpha-synuclein along with numerous other proteins, lipids, and cellular components. Their formation represents a failed attempt at cellular clearance:

1. Early stage: Hyperphosphorylated alpha-synuclein accumulates at the presynaptic terminal

2. Intermediate stage: Ubiquitinated oligomers and fibrils aggregate into visible inclusions

3. Late stage: Mature Lewy bodies contain a dense core surrounded by a halo of radiating filaments

The presence of numerous proteins in Lewy bodies reflects the broader disruption of cellular proteostasis in Parkinson’s disease. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}2

Cellular and Molecular Interactors

Protein Partners in Aggregation

Alpha-synuclein aggregation is modulated by interactions with numerous cellular proteins:

Lipid Interactions and Membrane Effects

The interaction of alpha-synuclein with lipid membranes is a critical aspect of its biology:

• Membrane binding: The N-terminal region binds to negatively charged phospholipids

• Membrane-induced folding: Lipid binding induces alpha-helical conformation

• Membrane disruption: Aggregated species can permeabilize membranes

• Raft association: Localization to lipid rafts may facilitate prion-like spread

Environmental and Lifestyle Factors

Risk Factors Promoting Aggregation

Various environmental and lifestyle factors influence alpha-synuclein aggregation:

Neurotoxin exposure: MPTP, rotenone, and other mitochondrial toxins promote alpha-synuclein pathology in experimental models, linking environmental exposures to disease pathogenesis.

Aging: The decline in cellular clearance mechanisms with age creates a permissive environment for protein aggregation. Decreased autophagy, proteasome activity, and chaperone function all contribute. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}3

Head trauma: Traumatic brain injury is associated with increased PD risk and may accelerate alpha-synuclein pathology through blood-brain barrier disruption and neuroinflammation.

Protective Factors

Several factors may reduce aggregation risk:

• Physical exercise: Promotes autophagy and enhances cellular clearance

• Caffeine: May reduce aggregation through adenosine receptor antagonism

• Anti-inflammatory drugs: Reduce neuroinflammation that promotes aggregation

Neuroinflammation and Glial Interactions

Microglial Activation

Alpha-synuclein pathology activates microglia through multiple mechanisms:

1. Direct recognition: Microglial TLR2 and TLR4 recognize aggregated alpha-synuclein

2. Complement activation: Opsonization with complement proteins promotes phagocytosis

3. Cytokine release: Activated microglia release TNF-alpha, IL-1beta, and IL-6

The resulting neuroinflammation creates a feed-forward loop where inflammatory cytokines promote further alpha-synuclein misfolding and release. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}4

Astrocyte Involvement

Astrocytes also participate in the response to alpha-synuclein pathology:

• Uptake and clearance: Astrocytes can internalize extracellular alpha-synuclein

• Inflammatory signaling: Activated astrocytes release pro-inflammatory mediators

• Metabolic support: Astrocytic dysfunction may reduce neuronal metabolic support

Interaction with Other Proteinopathies

Tau Co-Pathology

The co-occurrence of alpha-synuclein and tau pathology is common, particularly in certain clinical variants. The interaction between these two proteins includes:

• Cross-seeding: Tau fibrils can catalyze alpha-synuclein aggregation and vice versa

• Synergistic toxicity: Combined pathology produces greater neuronal loss

• Distinct anatomical patterns: Lewy bodies and neurofibrillary tangles follow different anatomical distributions

Amyloid-beta Interaction

In brains with both AD and PD pathology, amyloid-beta may influence alpha-synuclein aggregation:

• Modulation of aggregation kinetics: Amyloid-beta can accelerate or inhibit alpha-synuclein fibril formation depending on conditions

• Shared pathways: Both proteins involve similar cellular clearance mechanisms (UPS, autophagy) ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}5

Clinical Implications

Diagnostic Biomarkers

Alpha-synuclein aggregation provides potential biomarkers:

• Cerebrospinal fluid: Decreased alpha-synuclein and increased oligomers in PD

• Skin biopsies: Phospho-Ser129 alpha-synuclein in cutaneous nerves

• Blood-based markers: Alpha-synuclein in extracellular vesicles

Disease Progression Markers

The extent of alpha-synuclein pathology correlates with clinical severity:

• Braak staging: Predicts clinical progression based on anatomical spread

• Oligomer levels: Correlate with cognitive impairment in PD

• Lewy body density: Associated with faster disease progression

Autophagy Enhancement Strategies

The autophagy-lysosome pathway (ALP) represents a critical clearance mechanism for alpha-synuclein. Both macroautophagy and chaperone-mediated autophagy (CMA) contribute to intracellular alpha-synuclein turnover. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}6

Macroautophagy induction: mTOR inhibitors like rapamycin promote autophagy and reduce alpha-synuclein accumulation in cellular and animal models.

CMA activation: Enhancement of CMA can specifically target alpha-synuclein for lysosomal degradation, as the protein contains a CMA recognition motif.

Lysosomal function: Maintaining lysosomal acidity and enzyme activity is essential for effective clearance of alpha-synuclein aggregates. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}7

Mitochondrial Quality Control

Given the intimate relationship between alpha-synuclein and mitochondrial dysfunction, targeting mitochondrial quality control represents a promising approach:

• Complex I protection: Preserving mitochondrial complex I activity reduces oxidative stress and alpha-synuclein aggregation

• Mitophagy induction: Enhancing PINK1/Parkin-mediated mitophagy removes dysfunctional mitochondria

• Antioxidant therapy: Mitochondrial-targeted antioxidants like MitoQ address oxidative damage

These strategies address both the downstream consequences and upstream drivers of alpha-synuclein pathology. ^{3Staging of brain pathology related to sporadic Parkinson's disease2003 · Neurobiol Aging · PMID 12610656Open reference}8

Several novel approaches are under investigation:

1. Seed-specific inhibitors: Molecules that specifically block templated aggregation

2. Autophagy enhancers: Compounds that boost cellular clearance of alpha-synuclein

3. RNA-based therapies: ASOs and siRNA targeting SNCA mRNA

4. Cellular replacement: Strategies to replace lost neurons using stem cells

Biomarker Development

Improving diagnosis and tracking disease progression:

• Strain-specific detection: Distinguishing different alpha-synuclein conformations

• Real-time monitoring: PET ligands for alpha-synuclein pathology

• Multimodal markers: Combining alpha-synuclein with other biomarkers

α-Synuclein Aggregation Pathway

graph TD
    A["Native alpha-Synuclein<br/>Disordered Monomer"] --> B{"Triggering Factors"}
    B -->|"Oxidative Stress"| C["Conformational Change"]
    B -->|"Metal Ions (Fe2+, Cu2+)"| C
    B -->|"Lipid Interaction"| C
    B -->|"Low pH"| C

    C --> D["Oligomeric<br/>Intermediates"]
    D --> E["Protofibril<br/>Formation"]
    E --> F["Mature Amyloid<br/>Fibrils"]
    F --> G["Lewy Bodies and<br/>Lewy Neurites"]

    D --> H["Membrane Pore<br/>Formation"]
    H --> I["Ca2+ Influx and<br/>Toxicity"]

    D --> J["Mitochondrial<br/>Dysfunction"]
    J --> K["ROS Generation"]
    K --> C

    F --> L["Prion-like Spreading<br/>via Exosomes"]
    L --> M["Gut -> Vagus -><br/>Brainstem -> Cortex"]
    M --> N["Braak Staging<br/>of PD"]

    O["Anle138b<br/>Oligomer Modulator"] -.->|"Blocks"| D
    P["Prasinezumab<br/>Anti-alpha-Syn Ab"] -.->|"Clears"| D
    Q["LRRK2 Inhibitors"] -.->|"Reduces<br/>Phosphorylation"| C

    style G fill:#ff6666
    style I fill:#ff9999
    style N fill:#ff6666
    style O fill:#99ccff
    style P fill:#99ccff
    style Q fill:#99ccff

See Also

• Alpha-synuclein

• SNCA

• Parkinson’s disease

• Lewy body dementia

• Mitochondrial dysfunction in PD

• Autophagy in neurodegeneration

• Tau protein

• Amyloid-beta